Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
2.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

3.

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2017 Jun 15;77(12):3280-3292. doi: 10.1158/0008-5472.CAN-16-2808. Epub 2017 Apr 10. Erratum in: Cancer Res. 2019 Feb 15;79(4):873.

4.

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS.

Cancer Res. 2016 Aug 15;76(16):4752-64. doi: 10.1158/0008-5472.CAN-15-3393. Epub 2016 Apr 25.

5.
6.

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.

Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.

Breast Cancer Res. 2014 Jan 23;16(1):R9. doi: 10.1186/bcr3601.

7.

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL.

Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.

8.

Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.

Rexer BN, Arteaga CL.

Cancer Res. 2013 Jul 1;73(13):3817-20. doi: 10.1158/0008-5472.CAN-13-0687. Epub 2013 Jun 21. Review.

9.

Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy.

Rexer BN, Shyr Y, Arteaga CL.

J Clin Oncol. 2013 Jun 10;31(17):2073-5. doi: 10.1200/JCO.2012.48.5243. Epub 2013 May 6. No abstract available.

PMID:
23650407
10.

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Cancer Res. 2013 Jul 1;73(13):4075-85. doi: 10.1158/0008-5472.CAN-12-4579. Epub 2013 Apr 30.

12.

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

Miller TW, Rexer BN, Garrett JT, Arteaga CL.

Breast Cancer Res. 2011;13(6):224. doi: 10.1186/bcr3039. Epub 2011 Nov 1. Review.

13.

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.

Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM.

Cancer Res. 2011 Sep 15;71(18):5965-75. doi: 10.1158/0008-5472.CAN-11-0445. Epub 2011 Jul 20.

14.

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.

Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL.

Oncogene. 2011 Oct 6;30(40):4163-74. doi: 10.1038/onc.2011.130. Epub 2011 Apr 18.

15.

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.

Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL.

Oncogene. 2010 Sep 16;29(37):5193-203. doi: 10.1038/onc.2010.257. Epub 2010 Jun 28.

16.

Inhibition of PI3K and MEK: it is all about combinations and biomarkers.

Rexer BN, Ghosh R, Arteaga CL.

Clin Cancer Res. 2009 Jul 15;15(14):4518-20. doi: 10.1158/1078-0432.CCR-09-0872. Epub 2009 Jul 7.

17.

Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.

Rexer BN, Engelman JA, Arteaga CL.

Cell Cycle. 2009 Jan 1;8(1):18-22. Epub 2009 Jan 30. Review.

18.

Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema.

Lucey EC, Goldstein RH, Breuer R, Rexer BN, Ong DE, Snider GL.

Respiration. 2003 Mar-Apr;70(2):200-5.

PMID:
12740518
20.

Supplemental Content

Loading ...
Support Center